What Is Pharmacology - Rosiglitazone

Rosiglitazone

Rosiglitazone is useful in treating patient with type 2 diabetes mellitus. Rosiglitazone is a form of thiazolidinedione / oral hypoglycemic agent. Rosiglitazone will be metabolized by the P450 metabolism system in the liver.

Rosiglitazone will reduce the release of glucose from the liver. There will be reduced resistance to the insulin and increase sensitivity and uptake of insulin by muscle. The half life of rosiglitazone is around 6- 8 hours.

Rosiglitazone will cause the transcription of genes which code for the synthesis of protein that is essential for the function of the insulin. Rosiglitazone will activate the peroxisomal proliferator activated receptor in skeletal muscle, liver and adipose tissue.

Rosiglitazone will lower the blood glucose concentration. Rosiglitazone will bound to the plasma protein and rapidly absorbed via the oral route.

Rosiglitazone side effects may include hepatotoxicity, heart failure due to fluid retention and gain of weight.